In recent years, exosomes have emerged as promising and sensitive cancer biomarkers for use in disease diagnosis. Exosomes released from cancer cells after entering the circulation are transported in biological fluids along with their functional cargoes. Profiling the nucleic acids of exosomes derived from cancer cells by ultrasensitive next-generation sequencing and proteins by large-scale high-throughput proteomics can help us in early cancer detection, therapeutic stratification, and monitoring patient-specific responses to various cancer therapies. [Read more…]
EXO-Harvest to launch breakthrough scalable fixed-bed bioreactor platform for MSC and EVs manufacturing
Gosselies, Belgium, July 15, 2024 – EXO-Harvest, an affiliate of convEyXO, is thrilled to announce the successful launch of its cutting-edge multi-scale bioreactor platform for adherent cells and extracellular vesicles (EVs) production, in partnership with IPRATECH. The platform is now fully operational, marking a significant milestone in joint efforts to advance biotechnological solutions through engineering excellence. [Read more…]
Exosome Diagnostics May Predict Which Cancers are Invasive (and Which are “Safe”)
During the fall months of cancer campaigning, perhaps the biggest awareness remains in shadow: it is not yet possible to prevent patients from receiving needless treatment. As it stands, conservative estimates have determined that greater than 50% of men and women undergo unnecessary surgery and chemotherapy[1]. Many cancers do not deserve the dreaded name and are beginning to be labeled as non-progressive or indolent (“IDLEs”)[2] –a categorization that by itself may prevent untold psychological and physical trauma.
Exosome Diagnostics May Predict Invasiveness
Savvy researchers recognize that the most accurate information providing that distinction will come from what cells release into the blood like molecular mail[3]. Cancer or IDLEs, regardless of threat level, release clues regarding structural rearrangements, as well as tell-tail enzymes that allow cell migration, commandeer local metabolism, and resist their pollution.
Profiling these clues would enable scientists and doctors to determine the necessity and precision of therapy, rather than automatically prescribing aggressive treatment.
Such mail is not released “naked” but in little parcels of cell membrane called extracellular vesicles (EVs) or exosomes. Exosomes are produced by all cells in day to day bodily functions, but on a cell-for-cell basis, cancers release larger quantities of exosomes[4]. [Read more…]
Elevai Labs Releases Preliminary Positive Research on the Potential of Exosome Technology for Skin Health
Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai’s hUMSC derived exosomes (“ELEVAI exosomes™”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin’s extracellular matrix (“ECM”).
Data implies ELEVAI exosomes™ may be a source for proteins that typically decrease with age, and can be important components that prevent skin thinning, loss of elasticity and wrinkle formation.
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
NEW YORK, Dec. 3, 2024 — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietary exosome technology. [Read more…]
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 27
- Next Page »